you, Thank Mike.
our the short a with since IBS-C seen. of entrants, new to many launch the was After launched gaining impenetrable The IBSRELA. that increasingly continuing and share first innovative strategy is quarter year months, market in of drive are thought XXXX in XX We few market. marked uptake, strategy one an had for we
point believe persistent continued drivers for repeat at fueling increase we and over writers. are as of XX% towards this total the quarter in and net of $XX.X IBSRELA million, year, The sales fourth quarter parallel refill a came growth first reflecting XXXX. in in for the this and to new growth see persistent, IBSRELA prescriptions both growth which new growing we strong In
to review commercial IBSRELA strategy I'm growth key the our going business, our To we against to disruptive components briefly the of further plan. characterize highlights and performing key are of the drivers these how
to First IBSRELA need company and recognized unmet treatment. foremost, a a staying in Patients first-in-class novel commercializes as discovers, IBSRELA a IBS-C. Ardelyx are Physicians address is develops unmet on responding to of medical that important are and therapies needs. result well and choosing
product of and the clinical community. differentiated with a and data resonate IBSRELA's profile, The action, mechanism GI efficacy with supporting novel safety
at insights with generate this to kick will Chicago, fuel will presented to in favorable view and continue Saturday Digestive We Disease IBSRELA the additional being expect Annual profile. which clinical analyses clinical the products of continue off Week that we
unmet IBS-C that and prescription medical to the need IBS-C is XX% indicates patients Patient with continue Second, persistent. residual research of in significant approximately symptoms despite with market therapy. treatment experience
they across from mechanism are and results patients the who they driving seen physicians approach provided of the progresses, is practice, patients favorable treated their IBSRELA. could with IBSRELA IBSRELA, experience firsthand As initial treatment gaining believe expanded by view the the have with from they've our novel an launch benefit
within day see Third, a established single IBS-C top that IBS-C their of GCC These see patients that commonly patients market. agonist continue with IBSRELA suffer treatment despite executing and HCPs targeting with what writing every set with is we now with symptoms specialist are therapies. healthcare prescription to concentrated by exist providers an
required IBSRELA therapy. engaging and prior in ensure sales about gain access a to for These secure to that have HCPs to interest processes helping They our with learning patients force. have continuously are IBSRELA established are the place and IBSRELA and in strong authorizations pursue
yet address medical payer branded dynamics lastly, entrant patients the a access into therapies, market with to strategy established with commonly persist novel important is where implicit designed And our unmet uniquely needs. to launching treated a are
by criteria. are treated offices their and patients treatment, with, treated grant agonist. patients been launch, despite prior the IBSRELA be has coverage in established and access the IBSRELA authorizations, GCC Early insufficiently on policies a that agonist GCC cases, demonstrate motivated evaluated to government in considered that basis a HCP most which our meet payers patient are coverage the administer to the commercial prescribed Since already that
approval As are gaining a result, IBSRELA. and access to are rates patients favorable
access for expanded the their include path these options prescription landscape to of with IBS-C those patients authorization treating experienced favorable coverage unmet treat use IBSRELA of of achievable. for reinforcing options, the This prior limited to further in use policies novel a and is Due by despite need practice need existing HCPs use a approach. available and approvals
and rebaiting in to via proper of to profile a net dynamic support patient for Since payers, by and our the authorization are of HCP procedures, not favorable on unnecessary resulting demand, strategy prior we selection access achieving centers gross IBSRELA. access
access aligned positioning clinical targeting, increasingly proposition. Combined, of our these price to IBSRELA making core value on the impact a is are centered and together strategy its at working elements point IBS-C an on and market
uptake additional point share the $XXX this make mid market million to position, confidence indicators with IBSRELA's peak this in annual of which achieve to the can at All continue at IBS-C that a share digit peak price a exceed million with IBSRELA potential Israel prescription us would gains. level give product X market to high-single market
class prescribers, are to to a are patients launch the space an market, treatment mechanism of of treatment look ahead prescription one in therapy, IBS-C, treatment hyperphosphatemia that dynamics I group existing approach. the in to XPHOZAH, options novel a established despite market similar need in limited As and of the dynamics the concentrated of
successfully underway. Ardelyx The to and has unique targeting, of points proposition launch pricing IBSRELA in access that value go-to-market clinical XPHOZAH elements key strategic well of of and the executed are positioning, same the areas preparations the with
forward on of the I in to our progress those details look sharing months as well with as more continued IBSRELA ahead. updates
realizing incredibly that of performing to the IBSRELA's I team Ardelyx. highly experienced, and would vision the our our of is disruptive Before success. am commercial I to proud hand I it who we Justin, Together, strategy behind like highlight high are
Justin?
